Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | HNF4A | P41235 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29554351 | 0.88 | MAPT (0.39) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL29414575 | 0.88 | MAPT (0.39) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL19284747 | 0.88 | MAPT (0.39) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL19284743 | 0.88 | MAPT (0.39) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL27152060 | 0.86 | KDM4E (0.41) | KMT2AMEN1MAPTKDM4EPLA2G4B | |
| SCHEMBL19284774 | 0.84 | KDM4E (0.40) | KMT2AMEN1MAPTKDM4EPLA2G4B | |
| SCHEMBL19284772 | 0.84 | KDM4E (0.40) | KMT2AMEN1MAPTKDM4EPLA2G4B | |
| SCHEMBL17542371 | 0.83 | KDM4E (0.41) | KMT2AMEN1MAPTKDM4EPLA2G4B | |
| SCHEMBL23670407 | 0.83 | KDM4E (0.39) | KMT2AMEN1MAPTKDM4EPLA2G4B | |
| SCHEMBL17542370 | 0.83 | KDM4E (0.41) | KMT2AMEN1MAPTKDM4EPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067660-A1 | MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-29 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KMT2A 1766/4885MEN1 999/4885MAPT 3153/4885 |
| US-20240067660-A1 | MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | KMT2A 1986/4885MEN1 269/4885MAPT 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.